Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02800785 · ClinicalTrials.gov registry record · NA
The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 1,552
- Enrollment target
NCT02800785: Completed NA study, sponsored by University of Washington.
NCT02800785 is a NA study that has completed, run by University of Washington. The registered enrollment target is 1,552 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02800785, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,552 participants
- Enrollment target
Study Summary
For the past 130 years, appendectomy has been the standard treatment for appendicitis. Recent studies from Europe have challenged the notion that surgery is the best option, showing that antibiotics alone can treat appendicitis without a need for appendectomy in as many as 3 out of 4 patients and without safety issues for up to one year of follow up. Despite these results, it remains to be determined if the antibiotic strategy is as good as an appendectomy for the outcomes that most patients care about. The Patient-Centered Outcomes Research Institute (PCORI)-funded Comparison of Outcomes of Drugs and Appendectomy (CODA) trial will be the first American, and largest-ever randomized trial of the issue and its results should help surgeons and patients make more informed healthcare decisions.
Primary Outcome
The primary evaluation of patient-reported quality of life, as measured by the EuroQuol-5D at four-weeks, will be conducted using an intention-to-treat (ITT) analysis, where patients' data are analyzed according to the patients' randomized treatment assignment. EQ5D assesses health status in terms of five dimensions of health. The maximum score of 1 indicates the best health state, the minimum score is 0 (as score as bad as being dead).
Interventions
- PROCEDURE Appendectomy
- DRUG Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,552 participants |
| Start Date | 2016-05 |
| Est. Completion | 2021-09-01 |
| Phase | NA |
What the finished NCT02800785 record still lists
NCT02800785 is an interventional study that assigns participants to a tested intervention. Its 1,552 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 2 interventions - of which Appendectomy is the first listed.
NCT02800785 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02800785 about?
NCT02800785 is a clinical study titled "The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial". For the past 130 years, appendectomy has been the standard treatment for appendicitis. Recent studies from Europe have challenged the notion that surgery is the best option, showing that antibiotics alone can treat appendicitis without a need for appendectomy in as many as 3 out of 4 patients and wi...
What is the current status of trial NCT02800785?
This trial is currently completed. It is a NA study. The enrollment target is 1,552 participants. The study started on 2016-05. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT02800785?
The interventions under investigation include: Appendectomy (PROCEDURE), Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin (DRUG).
Who is sponsoring clinical trial NCT02800785?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02800785's enrollment target sits among peer trials
1,552 64th of 2000 higher than 1,937 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02650622 · 1,550 participants
Genetic and Metabolic Disease in Children
- NCT03961945 · 1,550 participants · NA
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
- NCT06729775 · 1,546 participants · NA
Disentangling the Role of Culture, Life Stage, and Information Design to Facilitate Equity in Data Report Back
- NCT06881069 · 1,560 participants · NA
Reach Through Equitable Implementation in Utah
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia